Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (371-380 of 536) with videos related to

Pageof 54
Sort By:
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
The Journal of Experimental Medicine|April 24, 2013
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationFlavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
The Journal of Experimental Medicine|January 21, 2017
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationFlavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
The Journal of Experimental Medicine|June 30, 2026
Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationFlavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
The Journal of Clinical Investigation|August 25, 2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemiaPaolo Neviani, Ramasamy Santhanam, Joshua J Oaks, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
Blood Advances|February 5, 2025
Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062Hyunjun Kang, Lianjun Zhang, Mohan R Kaadige, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2008
Prevention and treatment of cancer-related infectionsBrahm H Segal, Alison G Freifeld, Lindsey Robert Baden, et al.
Cancers|December 17, 2024
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)Hoda Pourhassan, Tina Nguyen, Dongyun Yang, et al.
Transplantation and Cellular Therapy|November 12, 2023
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation CyclophosphamideHany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Pageof 54

Showing results (371-380 of 536) with videos related to

Sort By:
Pageof 54
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
The Journal of Experimental Medicine|April 24, 2013
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationFlavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
The Journal of Experimental Medicine|January 21, 2017
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationFlavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
The Journal of Experimental Medicine|June 30, 2026
Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationFlavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
The Journal of Clinical Investigation|August 25, 2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemiaPaolo Neviani, Ramasamy Santhanam, Joshua J Oaks, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
Blood Advances|February 5, 2025
Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062Hyunjun Kang, Lianjun Zhang, Mohan R Kaadige, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2008
Prevention and treatment of cancer-related infectionsBrahm H Segal, Alison G Freifeld, Lindsey Robert Baden, et al.
Cancers|December 17, 2024
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)Hoda Pourhassan, Tina Nguyen, Dongyun Yang, et al.
Transplantation and Cellular Therapy|November 12, 2023
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation CyclophosphamideHany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Pageof 54